Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of SR141716 compared to placebo
on body weight and triglycerides changes over a period of 52 weeks.
Secondary objectives are:
- To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on
HDL-cholesterol and visceral fat area.
- To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks.
- To evaluate the pharmacokinetics of SR141716.